BioCentury
ARTICLE | Clinical News

Data for Oncopeptides' melflufen could support broader MM label

September 16, 2019 10:26 PM UTC

Oncopeptides remains on track to submit an NDA in 1Q20 for melflufen to treat multiple myeloma, as the latest data from a pivotal Phase II study showed an overall response rate of 23% among a subset of patients with relapsed or refractory extramedullary disease.

The Swedish biotech's goal with the Phase II HORIZON trial is to obtain data upon which it can base a submission seeking melflufen's approval in triple-class refractory MM, CEO Jakob Lindberg said on a conference call Monday. If Oncopeptides AB (SSE:ONCO) submits on time, the company could obtain accelerated approval as soon as next year of melflufen, a lipophilic peptide-conjugated alkylator...

BCIQ Company Profiles

Oncopeptides AB